Eli Lilly (NY: LLY )

913.72 +15.32 (+1.71%)
Official Closing Price Updated: 7:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,199,602
Open 903.00
Bid (Size) 910.05 (1)
Ask (Size) 913.50 (1)
Prev. Close 898.40
Today's Range 902.23 - 921.97
52wk Range 547.61 - 972.53
Shares Outstanding N/A
Dividend Yield 0.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Eli Lilly Was Such a Healthy Stock Today
The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday. 
Via The Motley Fool
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+54.29%
+54.29%
1 Month
+0.60%
+0.60%
3 Month
-0.47%
-0.47%
6 Month
+17.55%
+17.55%
1 Year
+59.81%
+59.81%

More News

Read More
(LLY) - Analyzing Eli Lilly's Short Interest
Via Benzinga
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
Via The Motley Fool
UNH: A Solid Healthcare Play In A Rotational Market
Via Talk Markets
Billion-Dollar News for Eli Lilly Stock Investors
Via The Motley Fool
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Via Benzinga
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
Via The Motley Fool
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Via Benzinga
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Via The Motley Fool
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Via Benzinga
Exposures Product Safety
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Via Benzinga
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Massive News for Hims & Hers Stock: The Truth About Today's Move
Via The Motley Fool
Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Via Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Via Benzinga
This IPO Biotech Stock Could Be the Next Eli Lilly
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Via Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.